Application of positron emission tomography imaging to cancer screening

S. Yasuda, M. Ide, H. Fujii, Tadaki Nakahara, Y. Mochizuki, W. Takahashi, A. Shohtsu

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can non-invasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1%). PET findings were true-positive in 36 of the 67 cancers (54%). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46%). 14 of these 31 (45%) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. (C) 2000 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)1607-1611
Number of pages5
JournalBritish Journal of Cancer
Volume83
Issue number12
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Early Detection of Cancer
Positron-Emission Tomography
Neoplasms
Fluorodeoxyglucose F18
Physical Examination
Ultrasonography
Thorax
Tomography
Costs and Cost Analysis

Keywords

  • Cancer screening
  • FDG
  • Glucose metabolism
  • PET
  • Tumour imaging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yasuda, S., Ide, M., Fujii, H., Nakahara, T., Mochizuki, Y., Takahashi, W., & Shohtsu, A. (2000). Application of positron emission tomography imaging to cancer screening. British Journal of Cancer, 83(12), 1607-1611. https://doi.org/10.1054/bjoc.2000.1496

Application of positron emission tomography imaging to cancer screening. / Yasuda, S.; Ide, M.; Fujii, H.; Nakahara, Tadaki; Mochizuki, Y.; Takahashi, W.; Shohtsu, A.

In: British Journal of Cancer, Vol. 83, No. 12, 2000, p. 1607-1611.

Research output: Contribution to journalArticle

Yasuda, S, Ide, M, Fujii, H, Nakahara, T, Mochizuki, Y, Takahashi, W & Shohtsu, A 2000, 'Application of positron emission tomography imaging to cancer screening', British Journal of Cancer, vol. 83, no. 12, pp. 1607-1611. https://doi.org/10.1054/bjoc.2000.1496
Yasuda, S. ; Ide, M. ; Fujii, H. ; Nakahara, Tadaki ; Mochizuki, Y. ; Takahashi, W. ; Shohtsu, A. / Application of positron emission tomography imaging to cancer screening. In: British Journal of Cancer. 2000 ; Vol. 83, No. 12. pp. 1607-1611.
@article{47b01ed101c54415a955d39750ff9a8c,
title = "Application of positron emission tomography imaging to cancer screening",
abstract = "Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can non-invasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1{\%}). PET findings were true-positive in 36 of the 67 cancers (54{\%}). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46{\%}). 14 of these 31 (45{\%}) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. (C) 2000 Cancer Research Campaign.",
keywords = "Cancer screening, FDG, Glucose metabolism, PET, Tumour imaging",
author = "S. Yasuda and M. Ide and H. Fujii and Tadaki Nakahara and Y. Mochizuki and W. Takahashi and A. Shohtsu",
year = "2000",
doi = "10.1054/bjoc.2000.1496",
language = "English",
volume = "83",
pages = "1607--1611",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Application of positron emission tomography imaging to cancer screening

AU - Yasuda, S.

AU - Ide, M.

AU - Fujii, H.

AU - Nakahara, Tadaki

AU - Mochizuki, Y.

AU - Takahashi, W.

AU - Shohtsu, A.

PY - 2000

Y1 - 2000

N2 - Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can non-invasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1%). PET findings were true-positive in 36 of the 67 cancers (54%). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46%). 14 of these 31 (45%) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. (C) 2000 Cancer Research Campaign.

AB - Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can non-invasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1%). PET findings were true-positive in 36 of the 67 cancers (54%). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46%). 14 of these 31 (45%) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. (C) 2000 Cancer Research Campaign.

KW - Cancer screening

KW - FDG

KW - Glucose metabolism

KW - PET

KW - Tumour imaging

UR - http://www.scopus.com/inward/record.url?scp=0034548099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034548099&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1496

DO - 10.1054/bjoc.2000.1496

M3 - Article

C2 - 11104553

AN - SCOPUS:0034548099

VL - 83

SP - 1607

EP - 1611

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -